Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.49 |
| ▸ | HTR2A | P28223 | 2/20 | 0.49 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14997384 | 0.89 | HTR2A (0.61) | CXCR4HTR2ACACNA1BCHRM2CHRM3 | |
| SCHEMBL4285276 | 0.86 | CHRM4 (0.56) | CXCR4HTR2ACACNA1BHTR2CKCNH2 | |
| SCHEMBL4281379 | 0.85 | CACNA1B (0.67) | CACNA1B | |
| SCHEMBL4284277 | 0.85 | HTR2A (0.48) | ALDH1A1CXCR4HTR2ACACNA1BHTR2C | |
| SCHEMBL4285152 | 0.85 | SIGMAR1 (0.56) | ALDH1A1KDM4ECXCR4HTR2ACACNA1B | |
| SCHEMBL4286138 | 0.85 | MEN1 (0.50) | CXCR4HTR2ACACNA1BHTR2CSIGMAR1 | |
| SCHEMBL4285261 | 0.82 | CACNA1B (0.46) | ALDH1A1KDM4EHTR2ACACNA1BHTR2C | |
| SCHEMBL4277843 | 0.81 | ACHE (0.55) | ALDH1A1KDM4EHTR2ACACNA1BSIGMAR1 | |
| SCHEMBL4277944 | 0.81 | NPC1 (0.60) | ALDH1A1KDM4E | |
| SCHEMBL13541677 | 0.80 | CACNA1B (0.53) | ALDH1A1HTR2ACACNA1BHTR2COPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9000174-B2 | 4-phenylsulfonamidopiperidines as calcium channel blockers | PURDUE PHARMA L.P. (US) | 2015-04-07 | — | — | US | disclosed |
| EP-1814851-B1 | 4-PHENYLSULFONAMIDOPIPERIDINES AS CALCIUM CHANNEL BLOCKERS | EURO CELTIQUE SA (LU) | 2013-06-05 | — | — | EP | disclosed |
| US-20090105249-A1 | 4-phenylsulfonamidopiperidines as calcium channel blockers | EURO-CELTIQUE S.A. (LU) | 2009-04-23 | — | — | US | disclosed |
| CN-101044116-A | 4-phenylsulfonamidopiperidines as calcium channel blockers | EURO CELTIQUE SA (LU) | 2007-09-26 | — | — | CN | disclosed |
| EP-1814851-A2 | 4-PHENYLSULFONAMIDOPIPERIDINES AS CALCIUM CHANNEL BLOCKERS | EURO-CELTIQUE S.A. (LU) | 2007-08-08 | — | — | EP | disclosed |
| WO-2006040181-A2 | 4-PHENYLSULFONAMIDOPIPERIDINES AS CALCIUM CHANNEL BLOCKERS | EURO-CELTIQUE S.A. (LU) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105249-A1 | 4-phenylsulfonamidopiperidines as calcium channel blockers | CACNA1A, CACNA1E, CACNA1B | ALDH1A1 2001/4885KDM4E 1434/4885CXCR4 1171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.